Iovance Biotherapeutics reported a strong Q3 with revenues up about 80% year-over-year and a gross margin of 60%. The company reaffirmed its 2026 revenue guidance of $410–$420 million and holds a solid cash reserve of $376 million, expected to last until 2029. Its lead product Amtagvi shows durable market performance and expanding treatment centers, supporting competitive strength in oncology. The analyst maintains a Buy rating, highlighting operational progress, a deep pipeline, and upcoming regulatory catalysts as key investment drivers.
Following Iovance Biotherapeutics' strong Q3 report, its stock is showing positive momentum on Pluang. As of Nov 06, 2026 20:41 WIB, IOVA trades at USD 7.92, up 2.33% for the day, with a market cap of $3.49 billion. Investor interest appears solid, with 100% of Pluang orders on the buy side and a typical hold time of 4 days, reflecting active engagement despite the stock's 52-week range from $2.13 to $14.86.
Iovance Biotherapeutics' stock fell 46% following a downgrade to Hold due to over-optimism in its valuation. While the melanoma drug AMTAGVI (lifileucel) is gaining market traction, the potential for its use in non-small cell lung cancer (NSCLC) appe...
Iovance Biotherapeutics reported a record third quarter 2026 revenue of approximately $122 million, marking an 80% increase year-over-year driven by strong demand for its cancer therapy Amtagvi. The company highlighted significant clinical progress, ...
